Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial

American Society of Clinical Psychopharmacology [ASCP], May 2019

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial (Oral Presentation)

American Society of Clinical Psychopharmacology [ASCP], May 2019

AXS-05: A Mechanistically Novel Oral Therapeutic in Development for Neuropsychiatric Disorders

American Psychiatric Association Conference [APA], May 2019

AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer’s Disease

Alzheimer's Association International Conference [AAIC], July 2018

AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development

American Society of Clinical Psychopharmacology [ASCP], May 2018

Clinical Development of AXS-05 for Treatment Resistant Depression and Agitation Associated with Alzheimer’s Disease

American Psychiatric Association Conference [APA], May 2018